

- 09.00 *Registration and refreshments*
- 09.15 **Welcome/Network information** **Chair: Professor Cal MacLennan**
- 09.30 **Opening Address**
Professor Sir Brian Greenwood
*Manson Professor of Tropical Medicine, London School of Hygiene and Tropical Medicine, UK
Chair - BactiVac Network Advisory Board*
- 09.45 **MRC / BBSRC**
Dr Martin Broadstock, Programme Manager, Medical Research Council, UK
Dr Ceri-Wyn Thomas, Strategy and Policy Manager, Biotechnology & Biological Sciences Research Council, UK
- 10.10 **Making quality vaccines for Lower and Middle Income Countries**
Professor Gordon Dougan
GSK Professor of Molecular Microbiology, The Department of Medicine, Cambridge University, UK
- 10.40 *Refreshments*
- 11.15 **Role of developing country vaccine manufacturers in global vaccine supply**
Dr Satish Ravetkar
Executive Director, Serum Institute of India Pvt Ltd, India
- 11.45 **The challenge of bacterial vaccines for global health**
Dr Jerome Kim
Director General, The International Vaccine Institute (IVI), Republic of Korea
- 12.15 *Lunch*
- 13.15 **Livestock vaccines. Leading or lagging?**
Professor Rick Titball
Professor of Molecular Microbiology, University of Exeter, UK **Chair: Dr Ted Fjällman**
- 13.45 **Catalyst funding awards round 1 – project presentations : refer to page 2**
- 14.45 *Refreshments*
- 15.15 **Group photograph** **Chair: Dr Jo Dean**
- 15.30 **Speed dating session**
- 16.45 **Close of day programme**
- 18.30 **Conference dinner**
This will be held in The Fry Room, Edgbaston Park Hotel & Conference Centre, B15 2RS

The programme is subject to change

Page 1

Wednesday 20 March 2019: 13.45pm

Catalyst funding awards round 1 – Project presentations

Time	Presenter	Post Held	Institution	Project Title
13.45	Dr Roma Chilengi	Chief Scientific Officer	Centre for Infectious Disease Research in Zambia (Zambia)	Measurement of <i>Shigella</i> -specific antibodies in the first two years of life in Zambian children to refine correlates of protection and determine the optimal window for vaccination
13.50	Dr Sean Elias	Post-Doctoral Scientist	University of Oxford, UK	Measuring non-typhoidal Salmonella specific antibodies in oral fluid as a non-invasive alternative to serum.
13.55	Dr Boris Gavrilov	Director Biologics Development Facility	Huvepharma, Bulgaria	Supporting the development of a DIVA compatible glycoconjugate vaccine for brucellosis
14.00	Dr Michael Jarvis	Associate Professor	The Vaccine Group Ltd (TVG) Ltd	Attenuated herepesvirus-based vaccines for low-cost antibiotic-independent control of bacterial disease in livestock - a proof of concept study
14.05	Prof Constantino Lopez-Macias	Principal Investigator	Mexican Social Security Institute, Mexico	Improving the production of a multivalent experimental vaccine against the diseases induced by <i>Salmonella enterica</i>
14.10	Dr Pietro Mastroeni	Reader in Infection and Immunity	University of Cambridge, UK	Using General Modules for Membrane Antigens (GMMA) as multivalent <i>Salmonella</i> vaccines for Low-Middle Income Countries (LMIC) and travellers
14.15	Dr Esther Muthumbi	PhD Student , Research Medical Officer	KEMRI-Wellcome, Kenya	Using seroepidemiology of non-Typhoidal Salmonella (NTS) in Kenya to understand changes in risks of invasion and transmission and direct the clinical development programme for vaccines against NTS
14.20	Dr Arlo Randall	Director of Bioinformatics	Antigen Discovery, Inc, USA	Protein antibody markers of pneumococcal carriage in support of protein and whole cell vaccine trial design using panproteomic antibody screening
14.25	Dr Christine Rollier	Research Scientist	University of Oxford, UK	A novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections: preclinical proof of concept
14.30	Mr Michelo Simuyandi	Research Fellow	Centre for Infectious Disease Research in Zambia (Zambia)	Field evaluation and validation of a novel and rapid ETEC diagnostic assay in a resource limited setting
14.35	Dr Carla Solorzano Gonzalez	Post-Doctoral Researcher	Liverpool School of Tropical Medicine, UK	Identification of correlates of protection against pneumococcal colonization

- 08.30 *Registration* **Chair: Professor Richard Adegbola**
- 09.00 **Vaccines, an achievement of civilization and health insurance for the future**
Dr Rino Rappuoli
Chief Scientist & Head of External Research and Development at GlaxoSmithKline Vaccines, Italy
- 09.30 **Recombinant glycoconjugate vaccines**
Professor Brendan Wren
Professor of Microbial Pathogenesis, London School of Hygiene and Tropical Medicine, UK
- 10.00 **Wellcome: Vaccine strategies and initiatives**
Shobana Balasingam
Programme Officer, Wellcome Trust, UK
- 10.30 **Gonococcal vaccine preferred product characteristics and public health value proposition: Initial global stakeholder consultation *Catalyst funding award round 1 – project report***
Dr Sami Gottlieb, *Medical Officer, World Health Organisation (Switzerland)*
- 11.00 **Discussion & refreshments**
Advancing global health vaccines : pitfalls and obstacles
- 11.50 **Feedback from group discussions**
- 12.40 *Lunch* **Chair: Professor Adam Cunningham**
- 13.30 **Optimising existing vaccines**
Dr Alex Richter
Consultant in Clinical Immunology, University of Birmingham, UK
- 14.00 **Immunity to enteric bacterial pathogens**
Dr Marcela F Pasetti
Professor of Microbiology and Immunity, University of Maryland, USA
- 14.30 **Bacterial vaccine development: A research and development perspective**
Dr Annaliesa S Anderson
Vice President & Chief Scientific Officer for Bacterial Research, Pfizer Inc, USA
- 15.00 *Refreshments*
- 15.30 **Vaccine development in SMEs - the drivers behind early commercialisation**
Dr Ted Fjällman
Chief Executive Officer, Prokarium Ltd, UK
- 16.00 **GAS vaccines: WHO preferred product characteristics and R&D technical roadmap**
Dr Johan Vekemans
Medical Officer, World Health Organisation, Switzerland
- 16.30 **Closing remarks – BactiVac Directors**
Professor Calman MacLennan & Professor Adam Cunningham
- 16.45 **Close of conference**